![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C18H17N5O2 |
Molar mass | 335.367 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Panadiplon (U-78875) is ananxiolytic drug with a novelchemical structure that is not closely related to other drugs of this type. It has a similar pharmacological profile to thebenzodiazepine family of drugs, but with mainly anxiolytic properties and relatively littlesedative oramnestic effect, and so is classified as anonbenzodiazepine anxiolytic.[1]
Panadiplon acts as a high-affinityGABAA receptorpartial agonist,[2][3] but despite showing a useful effects profile of a potent anxiolytic with little sedative effects, panadiplon was discontinued from clinical development for use in humans after showing evidence of liver damage in both animals and human trials.[4][5] Panadiplon however continues to be used in animal research, mainly as a subtype-selective reference drug to compare other GABAA agonists against.[6][7]